기본 콘텐츠로 건너뛰기

Is China's Undervaluation an Investment Opportunity?

 Recently, while reading Hong Chun-wook’s Economic Topics, I explored the structural weakness of China's economy. The author presented a negative outlook on Chinese investments, citing demographic shifts and the urban-rural divide. 

Book Review Link

However, I see it differently. The FXI, a prominent Chinese large-cap ETF, has risen by about 20% this year, and global giants like Tencent, Alibaba, and Xiaomi continue their steady growth despite U.S.-China trade tensions and economic slowdowns. These companies hold significant global influence, and avoiding Chinese stocks solely due to market concerns may not be a prudent choice. Hence, I believe that instead of outright avoiding Chinese stocks, investors should focus on valuation to identify opportunities.


China vs. U.S.: Valuation Comparison

A key metric for stock market valuation is the P/E ratio (price-to-earnings ratio), which represents how much investors are willing to pay per unit of corporate earnings. A higher P/E ratio suggests overvaluation, while a lower P/E ratio indicates undervaluation. To compare Chinese and U.S. stock valuations, I examined the P/E ratios of FXI (China’s top 50 large-cap ETF) and VTI (an ETF covering the entire U.S. stock market).

P/E Chart, Compare to all world stock Index
P/E Ratio for each countries



As of June 16, the projected P/E ratio for FXI is 9.99, which falls within the five-year average range of 8.87–13.03, meaning the market is at a fair valuation. In contrast, the U.S. stock market, represented by VTI, has a P/E ratio of 24.45, exceeding its five-year average (20.06–23.81) and indicating an overvalued status.

Compared to other countries—including India, Australia, Germany, and Japan—China’s P/E remains low. Even when benchmarked against Brazil’s stock market, China is undervalued on a global scale.

This suggests that Chinese stocks are historically cheap, while U.S. stocks are relatively expensive.


Why Is China Undervalued?

Several factors contribute to China’s low valuations:

  1. Economic Growth Slowdown – Post-pandemic domestic market contraction, continued real estate crisis, and rising youth unemployment
  2. Government Policy RisksStrict regulatory policies under Xi Jinping’s administration, causing a decline in foreign investor confidence
  3. U.S.-China Trade Tensions – Tariff policies and intensified tech competition under Trump-era trade wars, accelerating U.S. corporate exits from China
  4. Taiwan Risks – Geopolitical instability, leading to capital outflows from China

Due to these factors, foreign investors remain cautious, resulting in continued low market valuations.


China’s Advanced Industries Are Growing

Despite these concerns, China’s AI, semiconductor, and renewable energy sectors are rapidly growing with strong state support. Leading Chinese companies include:

  • SMIC – China’s largest semiconductor manufacturer, holding about 5% of the global market share (2024 data)
  • BYD – The world's top-selling EV maker
  • CATL – The largest global EV battery manufacturer, commanding 37% of the global market share

Moreover, Chinese AI leaders like Baidu, Tencent, and Alibaba continue to dominate the global industry.

China’s government is actively fostering semiconductors, AI, and aerospace technologies through significant investments, infrastructure development, and consumer stimulus policies. Amid escalating U.S.-China tech competition, China is building its own independent technology ecosystem to reduce reliance on U.S. firms while expanding its global influence.


China ETFs: Recent Rebound & Long-Term Prospects

As noted earlier, FXI and other Chinese ETFs have shown a recent rebound, suggesting potential long-term investment opportunities. Meanwhile, India—often seen as China’s alternative—has reached an overvaluation phase, with MSCI India’s P/E ratio at 24.40, approaching U.S. levels. While India’s economic growth remains strong, the global supply chain still relies heavily on China, allowing for possible market recovery.

However, investing in Chinese stocks requires careful consideration of risks:

1. Political Risks

  • Xi Jinping’s strict regulations: Increased restrictions on corporate activities and market censorship
  • Potential exclusion of foreign firms: China’s push for domestic technological self-reliance may limit access for overseas businesses
2. Geopolitical Tensions
  • U.S.-China trade war: Ongoing tensions in semiconductors, AI, and cloud industries
  • Taiwan disputes: Rising military concerns threaten global supply chain stability
3. Economic Uncertainty
  • Weak domestic consumption: Declining consumer spending and rising youth unemployment
  • Real estate market crisis: Increased local government debt, slowing economic growth
4. Declining Foreign Investment Confidence
  • Capital outflows: Investors shifting from China to India in recent years
  • Corporate transparency concerns: Lack of accounting and operational transparency among Chinese firms

Investment Strategy for Chinese Stocks

Despite China’s undervaluation, investors must assess risks carefully. Balancing portfolios and focusing on high-growth industries like AI, semiconductors, and tech sectors is crucial. Additionally, maintaining a diversified approach across the U.S., India, and other markets remains advisable.

Ultimately, China’s stock market is undervalued, but macroeconomic weaknesses and political risks persist. However, with government-backed industrial growth and rebounding ETFs, investment opportunities may emerge. Strategic adjustments—considering volatility while observing China’s economic recovery and global investment trends—will be necessary for long-term success.

댓글

이 블로그의 인기 게시물

Why Did HIMS Stock Crash? A Deep Dive into Digital Healthcare Risks

The digital healthcare industry is growing rapidly, but it comes with significant risks. Recently, U.S.-based telehealth company Hims & Hers Health (HIMS) experienced a sharp stock drop, raising red flags for investors. This post explores HIMS’s business model, recent developments, and future outlook. What is Hims & Hers Health (HIMS)   Hims & Hers Health Inc. is a U.S. digital healthcare company offering a wide range of online health solutions( Hair loss treatment, Skin care, Sexual health, Mental health, Wellness (e.g., sleep aids, vitamins, weight management) ) . Through its platform, users complete a brief questionnaire via website or mobile app, which is reviewed by licensed professionals. If approved, prescriptions are delivered to the customer’s home. Some products are also available over-the-counter.  Why Is HIMS Popular?   HIMS operates on a Direct-to-Consumer (D2C) model , with most products offered via monthly subscriptions . This approach...

📊 Comparing 3 China Tech ETFs: DRAG vs. TIGER China Tech Top10 vs. KODEX China Tech Top10 — Which Strategy Fits You?

With valuations for Chinese tech stocks still appearing attractive, I explored three ETFs that take different strategic approaches to China's growth potential. Previously, I introduced the U.S.-listed DRAG ETF, and recently, Mirae Asset’s TIGER China Tech Top10 and Samsung Asset Management’s KODEX China Tech Top10 were listed on the Korean exchange. All three focus on concentrated portfolios of selected large-cap Chinese tech stocks—but their investment strategies differ significantly , and that’s what I want to highlight. The previous post is linked below ⬇️ China Stock Market Valuation   DRAG ETF : China Tech Leader ETF 1️⃣ Roundhill China Dragons ETF (DRAG) U.S.-listed | Focused investment in select Chinese tech giants AUM : $30.06M (₩41.3B approx., as of June 19, 2025) NAV : $25.01 Volume : 2,293 shares (as of June 12, 2025) Expense Ratio : 0.59% No. of Holdings : 6 Strategy : Active Top Holdings : Tencent, Alibaba, Xiaomi, BYD, Pinduoduo, Meituan 🔎 Key Features ...

Analysis of U.S. Healthcare Trends: Which Sectors Are Thriving?

 The U.S. healthcare industry is evolving rapidly, influenced by policy changes and technological innovation. The restructuring of healthcare under the Trump administration, along with the expansion of Health Services & Technology (HST) and Specialty Pharmacies , are key developments shaping the market. 1. Overview of the U.S. Healthcare System Unlike South Korea, the U.S. does not have a universal national health insurance system . Instead, it operates on a private insurance-driven healthcare model. Healthcare costs in the U.S. are among the highest in the world, and without insurance, patients face exorbitant medical expenses. As a result, private health insurance is essential, and many companies offer employee benefits that include health coverage. This has led to a highly competitive and active private insurance market . As of 2023, 17.6% of the U.S. population is aged 65 or older , and the average life expectancy is 79.3 years . Meanwhile, the mortality rate has decli...